Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
VANCOUVER, British Columbia, Jan. 05, 2017 -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Pfizer Inc. (NYSE:PFE). AbCellera will apply its proprietary monoclonal antibody (mAb) screening platform to attempt to discover function-modulating antibodies against undisclosed membrane protein targets.
Carl Hansen, founding CEO of AbCellera, commented: “We are increasingly recognized as a leader in high-performance antibody discovery. Our platform allows us to screen natural immune repertoires with unparalleled depth to unlock the most challenging discovery programs. This partnership reinforces our commitment to offer leading-edge antibody discovery capabilities and to create value for companies by providing access to our platform. We welcome the opportunity to work closely with the innovative team at Pfizer and look forward to building a lasting relationship.”
“We are pleased to work with the team at AbCellera using their innovative antibody discovery platform,” said Will Somers, Vice President of Biomedicines Design, Pfizer. “We hope this platform can aid in our research as we look to bring novel medicines to patients, seeking to discover modulators of a transmembrane protein in a therapeutically important target class.”
Under the terms of the agreement, AbCellera will receive an upfront payment and research support, and will be eligible to receive up to approximately $90 million in contingent milestone payments, as well as tiered mid-to-low single digit royalty payments based on Pfizer’s development and commercialization of antibodies that may be generated under this collaboration. Further terms of the agreement are not disclosed.
About AbCellera Biologics, Inc.
AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.
AbCellera’s lead technology is a proprietary single cell antibody discovery platform that provides pharmaceutical and biotechnology partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans.
Contact Kevin Heyries Telephone: 604.827.4151 Email: [email protected] Web: www.abcellera.com
